Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials).
Crutel V, Lambert E, Penelaud PF, Albarrán Severo C, Fuentes J, Rosier A, Hervás A, Marret S, Oliveira G, Parellada M, Kyaga S, Gouttefangeas S, Bertrand M, Ravel D, Falissard B.
Crutel V, et al. Among authors: kyaga s.
J Autism Dev Disord. 2021 Aug;51(8):2959-2972. doi: 10.1007/s10803-020-04709-8.
J Autism Dev Disord. 2021.
PMID: 33151500
Free PMC article.
Clinical Trial.